Cargando…

Ajulemic acid: potential treatment for chronic inflammation

Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive. In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability...

Descripción completa

Detalles Bibliográficos
Autor principal: Burstein, Sumner H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891661/
https://www.ncbi.nlm.nih.gov/pubmed/29638269
http://dx.doi.org/10.1002/prp2.394

Ejemplares similares